Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

This Phase II study assessed the efficacy and safety of topical GT20029 in 180 Chinese adult males with androgenetic alopecia. Participants were divided into six groups to receive either GT20029 (0.5% or 1.0%) or placebo, administered once daily or twice weekly for 12 weeks. Results showed significant increases in target area non-vellus hair count (TAHC) at Week 12 for all GT20029-treated groups, with the 0.5% QD and 1.0% BIW groups showing notable improvements over placebo. Hair width also improved significantly in the 1.0% BIW group compared to placebo. The incidence of treatment-emergent adverse events was similar across all groups and mostly mild. The study concluded that topical GT20029 is effective in promoting hair regrowth and is well-tolerated, suggesting its potential as a treatment for androgenetic alopecia. Further research is recommended to confirm these findings.